Fig. 3From: Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016Comparison of progression-free survival based on the change in circulating endothelial cell counts from baseline to day 8Back to article page